Immunovant, Inc.

IMVT Nasdaq SEC CIK 1764013
Follow Immunovant Weekly email: filings, results

Financials

Reported figures only · latest: Q2 2027 USD · US GAAP
Net income −$97.2M +23.1% vs same quarter last year
EPS, diluted −$0.47 +35.6% vs same quarter last year
Operating cash flow −$83.2M +18.8% vs same quarter last year
Net income by quarter
−$111.1M
−$106.4M
−$120.6M
−$126.5M
−$110.6M
−$147.9M
−$153.2M
−$97.2M
Q3 25 Q4 25 Q1 26 Q2 26 Q3 26 Q4 26 Q1 27 Q2 27

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
−$600M−$400M−$200M$0FY18FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearNet income
FY26−$505.6M
FY25−$413.8M
FY24−$259.3M
FY23−$211M
FY22−$156.7M
FY21−$107.4M
FY20−$66.4M
FY19−$28.6M
FY18-
Free cash flowOperating cash flow minus capital expenditure
−$600M−$400M−$200M$0FY18FY19FY20FY21FY22FY23FY24FY25FY26
Show the numbers
YearFree cash flow
FY26−$407.3M
FY25−$376.6M
FY24−$214.6M
FY23−$188.4M
FY22−$106.4M
FY21−$83.5M
FY20−$53.4M
FY19−$28.6M
FY18-